Sort by

Send to

Choose Destination

Links from PubMed

Items: 12


Preparation and Characterization of Gelonin-Melittin Fusion Biotoxin for Synergistically Enhanced Anti-Tumor Activity.

Shin MC, Min KA, Cheong H, Moon C, Huang Y, He H, Yang VC.

Pharm Res. 2016 Sep;33(9):2218-28. doi: 10.1007/s11095-016-1959-4. Epub 2016 Jun 1.


Cys34-PEGylated Human Serum Albumin for Drug Binding and Delivery.

Mehtala JG, Kulczar C, Lavan M, Knipp G, Wei A.

Bioconjug Chem. 2015 May 20;26(5):941-9. doi: 10.1021/acs.bioconjchem.5b00143. Epub 2015 May 8.


PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.

Shin MC, Zhang J, Min KA, He H, David AE, Huang Y, Yang VC.

Pharm Res. 2015 Aug;32(8):2690-703. doi: 10.1007/s11095-015-1653-y. Epub 2015 Feb 21.


Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.

Shin MC, Zhang J, Min KA, Lee K, Moon C, Balthasar JP, Yang VC.

J Control Release. 2014 Nov 28;194:197-210. doi: 10.1016/j.jconrel.2014.08.030. Epub 2014 Sep 7.


Recombinant TAT-gelonin fusion toxin: synthesis and characterization of heparin/protamine-regulated cell transduction.

Shin MC, Zhao J, Zhang J, Huang Y, He H, Wang M, Min KA, Yang VC.

J Biomed Mater Res A. 2015 Jan;103(1):409-19. doi: 10.1002/jbm.a.35188. Epub 2014 Apr 23.


Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity.

Shin MC, Zhang J, David AE, Trommer WE, Kwon YM, Min KA, Kim JH, Yang VC.

J Control Release. 2013 Nov 28;172(1):169-78. doi: 10.1016/j.jconrel.2013.08.016. Epub 2013 Aug 23.


Receptor-mediated delivery of engineered nucleases for genome modification.

Chen Z, Jaafar L, Agyekum DG, Xiao H, Wade MF, Kumaran RI, Spector DL, Bao G, Porteus MH, Dynan WS, Meiler SE.

Nucleic Acids Res. 2013 Oct;41(19):e182. doi: 10.1093/nar/gkt710. Epub 2013 Aug 16.


Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticles.

Su X, Yang N, Wittrup KD, Irvine DJ.

Biomacromolecules. 2013 Apr 8;14(4):1093-102. doi: 10.1021/bm3019906. Epub 2013 Mar 11.


Intranuclear delivery of a novel antibody-derived radiosensitizer targeting the DNA-dependent protein kinase catalytic subunit.

Xiong H, Lee RJ, Haura EB, Edwards JG, Dynan WS, Li S.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):1023-30. doi: 10.1016/j.ijrobp.2011.08.039. Epub 2011 Dec 2.


Site-specific folate conjugation to a cytotoxic protein.

Smith BD, Higgin JJ, Raines RT.

Bioorg Med Chem Lett. 2011 Sep 1;21(17):5029-32. doi: 10.1016/j.bmcl.2011.04.081. Epub 2011 Apr 24.


Preparation, characterization and targeting of micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells.

Li Q, Liu C, Zhao X, Zu Y, Wang Y, Zhang B, Zhao D, Zhao Q, Su L, Gao Y, Sun B.

Int J Nanomedicine. 2011;6:397-405. doi: 10.2147/IJN.S16144. Epub 2011 Feb 20.


Issues related to targeted delivery of proteins and peptides.

Lu Y, Yang J, Sega E.

AAPS J. 2006 Jul 21;8(3):E466-78. Review.

Items per page

Supplemental Content

Support Center